VWA3A基因变异与新生血管性AMD抗VEGF治疗反应相关
本研究在187例接受抗VEGF治疗的以色列nvAMD患者中进行全外显子芯片基因分型,并与三次注射后的视力变化关联,发现VWA3A基因变异与治疗反应相关,并在108例独立验证集中验证该变异次要等位基因与更差视力应答相关。
要点
- VWA3A基因变异次要等位基因与抗VEGF治疗后更差视力应答相关(验证集P=0.02)。
- 主要等位基因纯合子平均deltaVA为-0.214 logMAR(约增益10.7个ETDRS字母)。
- 次要等位基因携带者基线黄斑出血频率更高。
核心结论
- VWA3A基因变异与以色列nvAMD患者抗VEGF治疗更差应答相关。
研究设计与样本
- 全基因组关联研究,发现集187例接受抗VEGF治疗的以色列nvAMD患者,全外显子芯片约500,000个变异。
- 独立验证集108例nvAMD患者,对两个领先关联变异进行基因分型。
主要发现
- 线性回归分析5,353,842个变异发现5个外显子变异关联P值小于6×10-5。
- VWA3A基因顶级变异P=1.77×10-6,在验证集中次要等位基因与更差治疗反应相关(P=0.02)。
- 发现集加验证集平均deltaVA:主要等位基因纯合子-0.214 logMAR(约增益10.7个ETDRS字母),杂合子0.172 logMAR(约损失8.6个ETDRS字母),次要等位基因纯合子0.21 logMAR(约损失10.5个ETDRS字母)。
- 次要等位基因携带者基线黄斑出血频率更高。
临床怎么用
- VWA3A变异可能作为nvAMD患者抗VEGF治疗应答的遗传标记,但需进一步验证。
局限性
- 研究仅纳入以色列患者,样本量有限,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Anti-vascular endothelial growth factor (VEGF) therapy for neovascular AMD (nvAMD) obtains a variable outcome. We performed a genome-wide association study for anti-VEGF treatment response in nvAMD to identify variants potentially underlying such a variable outcome. METHODS: Israeli patients with nvAMD who underwent anti-VEGF treatment (n = 187) were genotyped on a whole exome chip containing approximately 500,000 variants. Genotyping was correlated with delta visual acuity (deltaVA) between baseline and after three injections of anti-VEGF. Top principal components, age, and baseline VA were included in the analysis. Two lead associated variants were genotyped in an independent validation set of patients with nvAMD (n = 108). RESULTS: Linear regression analysis on 5,353,842 variants revealed five exonic variants with an association P value of less than 6 × 10-5. The top variant in the gene VWA3A (P = 1.77 × 10-6) was tested in the validation cohort. The minor allele of the VWA3A variant was associated with worse response to treatment (P = 0.02). The average deltaVA of discovery plus validation was -0.214 logMAR (≈ a gain of 10.7 Early Treatment Diabetic Retinopathy Study letters) for homozygote for the major allele, 0.172 logMAR for heterozygotes (≈ a loss of 8.6 Early Treatment Diabetic Retinopathy Study letters), and 0.21 logMAR for homozygote for the minor allele (≈ a loss of 10.5 Early Treatment Diabetic Retinopathy Study letters). Minor allele carriers had a higher frequency of macular hemorrhage at baseline. CONCLUSIONS: An VWA3A gene variant was associated with worse response to anti-VEGF treatment in Israeli patients with nvAMD. The VWA3A protein is a precursor of the multimeric von Willebrand factor which is involved in blood coagulation, a system previously associated with nvAMD.
引用
- Grunin M, Beykin G, Rahmani E, et al. Association of a Variant in VWA3A with Response to Anti-Vascular Endothelial Growth Factor Treatment in Neovascular AMD. Invest Ophthalmol Vis Sci. 2020. PMID: 32106291. doi:10.1167/iovs.61.2.48
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。